santin

Santin (5,7-Dihydroxy-3,6,4'-trimethoxyflavone) is a flavonoid extracted from birch buds exerting antiproliferative, anti-influenza activity and anti-cancer activity. Santin can be used in studies about anti-IAV drugs.

Santin (Standard) is a reference standard for research and analysis in studies involving Santin. Santin (5,7-Dihydroxy-3,6,4'-trimethoxyflavone) is a flavonoid extracted from birch buds exerting antiproliferative, anti-influenza activity and anti-cancer activity. Santin can be used in studies about anti-IAV drugs.

4-O-Demethylmanassantin A is a useful organic compound for research related to life sciences. The catalog number is T123894 and the CAS number is 943011-47-0.

4-O-Demethylmanassantin B is a useful organic compound for research related to life sciences. The catalog number is T124374 and the CAS number is 695151-38-3.

5',7'-Diacetylsantin is a useful organic compound for research related to life sciences and the catalog number is T131461.

Manassantin B (Standard) is a reference standard for research and analysis in studies involving Manassantin B. Manassantin B is a potent inhibitor of NF-κB activation by the suppression of transciptional activity of RelA/p65 subunit of NF-κB. It also possesses anti-EBV lytic replication activity. Manassantin B inhibits interleukin-6-induced signal transducer and activator of transcription 3 activation in Hep3B cells, it has potential as a potent anti-inflammatory drug for use in pathological processes such as sepsis or acute lung injury. Manassantin B exerts antifibrotic activity in HSC-T6 cells, in part, via inhibition of cell proliferation and decrease of collagen production.

Manassantin A (Standard) is a reference standard for research and analysis in studies involving Manassantin A. Manassantin A is a high potent HIF-1 inhibitor, it protects the gastric mucosa from ethanol-induced acute gastric injury, and suggest that these protective effects might be associated with COX/PGE2 stimulation, inhibition of iNOS production and NF-κB activation, and improvements in the antioxidant and anti-inflammatory status.Manassantin A represents a potential therapeutic approach for the treatment of airway allergic-inflammatory diseases. Manassantin A inhibits cAMP-induced melanin production by down-regulating the gene expressions of MITF and tyrosinase in melanocytes.

Manassantin A is a high potent HIF-1 inhibitor, it protects the gastric mucosa from ethanol-induced acute gastric injury, and suggest that these protective effects might be associated with COX/PGE2 stimulation, inhibition of iNOS production and NF-κB act

Manassantin B is a potent inhibitor of NF-κB activation by the suppression of transciptional activity of RelA/p65 subunit of NF-κB. It also possesses anti-EBV lytic replication activity. Manassantin B inhibits interleukin-6-induced signal transducer and activator of transcription 3 activation in Hep3B cells, it has potential as a potent anti-inflammatory drug for use in pathological processes such as sepsis or acute lung injury. Manassantin B exerts antifibrotic activity in HSC-T6 cells, in part, via inhibition of cell proliferation and decrease of collagen production.